[{"NetIncomeLoss_3_Q3_USD":-19973000.0,"OtherAssetsNoncurrent_0_Q3_USD":1000.0,"Liabilities_0_Q3_USD":11791000.0,"RestructuringAndRelatedCostExpectedCostRemaining1_0_Q3_USD":100000.0,"OperatingLeaseLiability_0_Q3_USD":406000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"GeneralAndAdministrativeExpense_3_Q3_USD":7728000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":2299000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":51463002.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":55787793.0,"CommitmentsAndContingencies_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":2619000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_3_Q3_USD":300000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-864000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q3_USD":100000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q3_USD":3900000.0,"PaymentsForRestructuring_3_Q3_USD":1468000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":1948000.0,"AssetsCurrent_0_Q3_USD":31972000.0,"OtherNoncashIncomeExpense_3_Q3_USD":-34000.0,"RestructuringCharges_3_Q3_USD":291000.0,"RestructuringCharges_1_Q3_USD":100000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":13447000.0,"CommonStockSharesIssued_0_Q3_shares":57074478.0,"Assets_0_Q3_USD":32833000.0,"UnrealizedGainLossOnInvestments_1_Q3_USD":0.0,"UnrealizedGainLossOnInvestments_3_Q3_USD":0.0,"InterestPaidNet_3_Q3_USD":198000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-5494000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-19973000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_1_Q3_USD":0.0,"ShortTermInvestments_0_Q3_USD":0.0,"ClassOfWarrantOrRightOutstanding_0_Q3_shares":7535815.0,"ResearchAndDevelopmentExpense_3_Q3_USD":13050000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":3111000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":500000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":-2826000.0,"AccountsReceivableNetCurrent_0_Q3_USD":57000.0,"CommonStockValue_0_Q3_USD":571000.0,"IncomeTaxExaminationPenaltiesAndInterestExpense_3_Q3_USD":0.0,"IncomeTaxExaminationPenaltiesAndInterestExpense_1_Q3_USD":0.0,"ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_3_Q3_USD":26000.0,"LongTermNotesPayable_0_Q3_USD":4127000.0,"RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_3_Q3_position":44.0,"DepreciationDepletionAndAmortization_3_Q3_USD":189000.0,"DepreciationDepletionAndAmortization_1_Q3_USD":100000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":23628000.0,"RealizedInvestmentGainsLosses_3_Q3_USD":0.0,"RealizedInvestmentGainsLosses_1_Q3_USD":0.0,"InterestAndDebtExpense_3_Q3_USD":328000.0,"InterestAndDebtExpense_1_Q3_USD":93000.0,"PaymentsOfStockIssuanceCosts_3_Q3_USD":1303000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":2000000.0,"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0_Q3_shares":7535815.0,"ProceedsFromNotesPayable_3_Q3_USD":1726000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-19973000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-5494000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_3_Q3_USD":0.0,"ShareBasedCompensation_3_Q3_USD":1902000.0,"RestructuringAndRelatedCostCostIncurredToDate1_0_Q3_USD":2400000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":490000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":24499000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":5233000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":-51000.0,"CommonStockSharesOutstanding_0_Q3_shares":57074478.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":0.0,"AmortizationOfFinancingCosts_3_Q3_USD":281000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":3471000.0,"ProceedsFromSaleOfPropertyPlantAndEquipment_3_Q3_USD":1000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":615000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-20343000.0,"LiabilitiesCurrent_0_Q3_USD":7558000.0,"AccountsPayableCurrent_0_Q3_USD":232000.0,"SaleOfStockNumberOfSharesIssuedInTransaction_3_Q3_shares":2557544.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-188145000.0,"RestructuringReserveAccrualAdjustment1_3_Q3_USD":41000.0,"NonoperatingIncomeExpense_1_Q3_USD":9000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":30079000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":1836000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":13000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":81000.0,"AdditionalPaidInCapital_0_Q3_USD":208616000.0,"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0_Q3_USD":1.13,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q3_USD":10000.0,"NumberOfOperatingSegments_3_Q3_segment":1.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":370000.0,"NetIncomeLoss_1_Q3_USD":-5494000.0,"NonoperatingIncomeExpense_3_Q3_USD":137000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_1_Q3_USD":0.0,"RevenueFromContractWithCustomerIncludingAssessedTax_3_Q3_USD":996000.0,"AccruedRentCurrent_0_Q3_USD":0.0,"RepaymentsOfNotesPayable_3_Q3_USD":1333000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.01,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-726000.0,"CommonStockSharesAuthorized_0_Q3_shares":100000000.0,"ImpairmentOfLongLivedAssetsHeldForUse_3_Q3_USD":0.0,"ImpairmentOfLongLivedAssetsHeldForUse_1_Q3_USD":0.0,"OperatingIncomeLoss_3_Q3_USD":-19782000.0,"OperatingIncomeLoss_1_Q3_USD":-5410000.0,"NotesPayableCurrent_0_Q3_USD":4707000.0,"RestructuringReserve_0_Q3_USD":379000.0,"PreferredStockValue_0_Q3_USD":0.0,"RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3_Q3_pure":0.5,"LiabilitiesAndStockholdersEquity_0_Q3_USD":32833000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":581000.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":1902000.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":3841000.0,"OperatingExpenses_3_Q3_USD":20778000.0,"OperatingExpenses_1_Q3_USD":5410000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-0.39,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.1,"OtherLiabilitiesNoncurrent_0_Q3_USD":106000.0,"StockholdersEquity_0_Q3_USD":21042000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":53000.0,"AccretionExpense_3_Q3_USD":138000.0,"LongTermInvestments_0_Q3_USD":0.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":1000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.01,"AccruedProfessionalFeesCurrent_0_Q3_USD":137000.0,"Ticker":"VRDN","CIK":"1590750","name":"MIRAGEN THERAPEUTICS, INC.","OfficialName":"Viridian Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"445189274.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]